Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

v3.20.1
Intangible Assets
 3 Months Ended
Dec. 31, 2019
Intangible Assets  
Intangible Assets

7. Intangible Assets

The Company’s intangible assets consisted of the following:

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

September 30,

 

Estimated Useful

 

    

2019

    

2019

    

Life (In Months)

Clinical trial data

 

$

250,000

 

$

250,000

 

 6

Accumulated amortization

 

 

(229,167)

 

 

(104,167)

 

  

Intangible assets, net

 

$

20,833

 

$

145,833

 

  

 

Amortization expense for the three months ended December 31, 2019 was approximately $0.13 million. Amortization expense for the three months ended December 31, 2018 was $0.